kaiyan zhang's Highlights on '红德智库'

PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.

www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/114548-parp-inhibition-suppresses-gr-mycn-cdk5-rb1-e2f1-signaling-and-neuroendocrine-differentiation-in-castration-resistant-prostate-cancer.html

Apr 11, 2020

Whole Genome and Transcriptional Analysis of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Demonstrates Intra-Class Heterogeneity.

www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/111366-whole-genome-and-transcriptional-analysis-of-treatment-emergent-small-cell-neuroendocrine-prostate-cancer-demonstrates-intra-class-heterogeneity.html

Apr 11, 2020

Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.

www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/108923-serum-neuroendocrine-markers-predict-therapy-outcome-of-patients-with-metastatic-castration-resistant-prostate-cancer-a-meta-analysis.html

Apr 11, 2020

Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis

www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/96102-contemporary-incidence-and-cancer-control-outcomes-of-primary-neuroendocrine-prostate-cancer-a-seer-database-analysis.html

Apr 11, 2020

The many faces of neuroendocrine differentiation in prostate cancer progression - Abstract

www.urotoday.com/recent-abstracts/urologic-oncology/investigative-urology/71847-the-many-faces-of-neuroendocrine-differentiation-in-prostate-cancer-progression-abstract.html

Apr 11, 2020

Systems Medicine approaches to improving understanding, treatment, and clinical management of Neuroendocrine Prostate Cancer

www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/88807-systems-medicine-approaches-to-improving-understanding-treatment-and-clinical-management-of-neuroendocrine-prostate-cancer.html

Apr 11, 2020

TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.

www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/115060-tcf4-induces-enzalutamide-resistance-via-neuroendocrine-differentiation-in-prostate-cancer.html

Apr 11, 2020

APCCC 2019: Neuroendocrine Prostate Cancer Spectrum - Diagnosis and Treatment

www.urotoday.com/conference-highlights/apccc-2019/114635-apccc-2019-neuroendocrine-prostate-cancer-spectrum-diagnosis-and-treatment.html

Apr 10, 2020

ASCO GU 2020: (NIVOSWITCH) - Switch to Nivolumab with TKI Continuation After 12 Weeks of TKI Induction Therapy in Metastatic Renal Cell Carcinoma

www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119336-asco-gu-2020-nivoswitch-switch-to-nivolumab-with-tki-continuation-after-12-weeks-of-tki-induction-therapy-in-metastatic-renal-cell-carcinoma.html

Mar 30, 2020

ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Neoadjuvant Therapy for Localized RCC

www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119343-asco-gu-2020-challenging-clinical-scenarios-in-the-management-of-renal-cell-carcinoma-neoadjuvant-therapy-for-localized-rcc.html

Mar 30, 2020

ASCO GU 2020: Overall Survival Results for Durvalumab and Savolitinib in Metastatic Papillary Renal Cancer — CALYPSO trial

www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119363-asco-gu-2020-overall-survival-results-for-durvalumab-and-savolitinib-in-metastatic-papillary-renal-cancer-calypso-trial.html

Mar 30, 2020

ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma - From the Perspective of a Radiologist

www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119359-asco-gu-2020-challenging-clinical-scenarios-in-the-management-of-renal-cell-carcinoma-from-the-perspective-of-a-radiologist.html

Mar 30, 2020

ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma - From the Perspective of a Radiologist

Mar 30, 2020

ASCO GU 2020: Comparing Nivolumab versus Everolimus with >5 years of Follow-up in Patients with Advanced Renal Cell Carcinoma: A Final Analysis of the CheckMate 025 Trial

www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119378-asco-gu-2020-comparting-nivolumab-versus-everolimus-with-5-years-of-follow-up-in-patients-with-advanced-renal-cell-carcinoma-a-final-analysis-of-the-checkmate-025-trial.html

Mar 30, 2020

ASCO GU 2020: Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy

www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119346-asco-gu-2020-cytoreductive-nephrectomy-for-metastatic-renal-cell-carcinoma-treated-with-immune-checkpoint-inhibitors-or-targeted-therapy.html

Mar 28, 2020

ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Surgeon’s Perspective

www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119418-asco-gu-2020-best-of-journals-renal-cell-carcinoma-the-surgeon-s-perspective.html

Mar 25, 2020

5 Data transformation | R for Data Science: Exercise Solutions

jrnold.github.io/r4ds-exercise-solutions/transform.html

Feb 14, 2020

R for Data Science Solutions

jrnold.github.io/r4ds-exercise-solutions/data-visualisation.html

Feb 14, 2020

Pattern of Metastases in Relation to Characteristics of Primary Tumor and Treatment in Patients with Disseminated Urothelial Carcinoma

www.sciencedirect.com/science/article/pii/S0022534701665625

Nov 29, 2017

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

www.sciencedirect.com/science/article/pii/S1470204508703401

Nov 23, 2017

红德智库

www.hongdezk.com/index.html

Nov 23, 2017

Annotating the law | Hypothes.is

web.hypothes.is/

Nov 23, 2017